Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Lorenz Frehner; Simon Haefliger; Ferdinando Cerciello; Tobias Grob; Sabine Schmid

doi:10.1159/000533572

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Case Rep Oncol. 2023 Sep 12;16(1):871-877. doi: 10.1159/000533572. eCollection 2023 Jan-Dec.

Authors

Lorenz Frehner¹, Simon Haefliger¹, Ferdinando Cerciello¹, Tobias Grob², Sabine Schmid¹

Affiliations

¹ Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

Abstract

In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these agents in patients with NSCLC and NTRK2 fusion are available. We present a case of a female patient with NTRK2-positive NSCLC with a complete ongoing response on therapy with larotrectinib, suggesting efficacy of first-generation TRK inhibitors also in NTRK2-positive NSCLC.

Keywords: NTRK2; Non-small cell lung cancer; Targeted therapy.

Publication types

Case Reports

Grants and funding

There was no funding for this study.